CO2024005880A2 - Conjugados que comprenden fósforo (v) y una fracción molecular de camptotecina - Google Patents
Conjugados que comprenden fósforo (v) y una fracción molecular de camptotecinaInfo
- Publication number
- CO2024005880A2 CO2024005880A2 CONC2024/0005880A CO2024005880A CO2024005880A2 CO 2024005880 A2 CO2024005880 A2 CO 2024005880A2 CO 2024005880 A CO2024005880 A CO 2024005880A CO 2024005880 A2 CO2024005880 A2 CO 2024005880A2
- Authority
- CO
- Colombia
- Prior art keywords
- camptothecin
- conjugates
- phosphorus
- molecular fraction
- relates
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207284 | 2021-11-09 | ||
| PCT/EP2022/081371 WO2023083919A1 (en) | 2021-11-09 | 2022-11-09 | Conjugates comprising a phosphorus (v) and a camptothecin moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024005880A2 true CO2024005880A2 (es) | 2024-07-08 |
Family
ID=78592674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0005880A CO2024005880A2 (es) | 2021-11-09 | 2024-05-06 | Conjugados que comprenden fósforo (v) y una fracción molecular de camptotecina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230158154A1 (enExample) |
| EP (1) | EP4429709A1 (enExample) |
| JP (1) | JP2024540692A (enExample) |
| KR (1) | KR20240100415A (enExample) |
| CN (1) | CN118302198A (enExample) |
| AU (1) | AU2022386680A1 (enExample) |
| CA (1) | CA3237379A1 (enExample) |
| CL (1) | CL2024001373A1 (enExample) |
| CO (1) | CO2024005880A2 (enExample) |
| DE (1) | DE22817180T1 (enExample) |
| ES (1) | ES3001145T1 (enExample) |
| IL (1) | IL312677A (enExample) |
| MX (1) | MX2024005545A (enExample) |
| PE (1) | PE20242114A1 (enExample) |
| TW (1) | TW202339803A (enExample) |
| WO (1) | WO2023083919A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| AU2024332412A1 (en) | 2023-09-01 | 2026-03-12 | Tubulis Gmbh | Methods of preparing phosphonamidate compounds |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| WO2026016639A1 (zh) * | 2024-07-19 | 2026-01-22 | 昆山新蕴达生物科技有限公司 | 一种靶向adam-9的抗体-药物偶联物及其制备方法和用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| EP0964702B1 (en) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| SV2007002227A (es) | 2004-09-10 | 2007-03-20 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 |
| US7687496B2 (en) * | 2007-10-16 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | C7-substituted camptothecin analogs |
| NZ610239A (en) | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| ES3029483T3 (en) * | 2008-09-17 | 2025-06-24 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| JP7137474B2 (ja) | 2016-03-15 | 2022-09-14 | メルサナ セラピューティクス，インコーポレイティド | ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法 |
| AU2017320913B2 (en) | 2016-09-01 | 2024-08-15 | Forschungsverbund Berlin E.V. | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates |
| KR102772724B1 (ko) | 2018-03-07 | 2025-02-24 | 포슝스베르분드 베를린 에.베. | 알켄 또는 알킨-포스포노티올레이트 및 -포스포네이트로의 화학선택적 티올-접합 |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| EP3976112A1 (en) | 2019-06-03 | 2022-04-06 | Synaffix B.V. | Acetal-based cleavable linkers |
| IL289094A (en) * | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| DK3983363T3 (da) * | 2019-06-17 | 2024-06-24 | Tagworks Pharmaceuticals B V | Forbindelser til hurtig og effektiv klikfrigivelse |
-
2022
- 2022-11-09 ES ES22817180T patent/ES3001145T1/es active Pending
- 2022-11-09 PE PE2024001006A patent/PE20242114A1/es unknown
- 2022-11-09 KR KR1020247019075A patent/KR20240100415A/ko active Pending
- 2022-11-09 TW TW111142866A patent/TW202339803A/zh unknown
- 2022-11-09 MX MX2024005545A patent/MX2024005545A/es unknown
- 2022-11-09 IL IL312677A patent/IL312677A/en unknown
- 2022-11-09 US US18/054,063 patent/US20230158154A1/en active Pending
- 2022-11-09 DE DE22817180.7T patent/DE22817180T1/de active Pending
- 2022-11-09 CA CA3237379A patent/CA3237379A1/en active Pending
- 2022-11-09 CN CN202280074840.5A patent/CN118302198A/zh active Pending
- 2022-11-09 AU AU2022386680A patent/AU2022386680A1/en active Pending
- 2022-11-09 JP JP2024549577A patent/JP2024540692A/ja active Pending
- 2022-11-09 WO PCT/EP2022/081371 patent/WO2023083919A1/en not_active Ceased
- 2022-11-09 EP EP22817180.7A patent/EP4429709A1/en active Pending
-
2024
- 2024-05-06 CO CONC2024/0005880A patent/CO2024005880A2/es unknown
- 2024-05-06 CL CL2024001373A patent/CL2024001373A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE22817180T1 (de) | 2024-12-12 |
| US20230158154A1 (en) | 2023-05-25 |
| PE20242114A1 (es) | 2024-10-28 |
| EP4429709A1 (en) | 2024-09-18 |
| ES3001145T1 (es) | 2025-03-04 |
| JP2024540692A (ja) | 2024-10-31 |
| KR20240100415A (ko) | 2024-07-01 |
| IL312677A (en) | 2024-07-01 |
| CL2024001373A1 (es) | 2024-10-25 |
| TW202339803A (zh) | 2023-10-16 |
| CA3237379A1 (en) | 2023-05-19 |
| CN118302198A (zh) | 2024-07-05 |
| AU2022386680A1 (en) | 2024-06-20 |
| WO2023083919A1 (en) | 2023-05-19 |
| MX2024005545A (es) | 2024-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024005880A2 (es) | Conjugados que comprenden fósforo (v) y una fracción molecular de camptotecina | |
| CO2024005877A2 (es) | Conjugados que comprenden fósforo (v) y una fracción molecular de droga | |
| MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
| BR112016002829A2 (pt) | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi | |
| BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
| CR20210541A (es) | Compuestos y conjugados de estos | |
| MX368966B (es) | Conjugados de proteina-polimero-farmaco. | |
| EA201992081A1 (ru) | Конъюгирование цитотоксических лекарственных средств посредством бис-связывания | |
| BR112013023015A8 (pt) | conjugado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina. | |
| CO2024006160A2 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| MX2018012460A (es) | Composiciones de conjugados de acido nucleico dirigido. | |
| BRPI0611872B8 (pt) | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica | |
| BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
| NI201300010A (es) | Derivados anticancerosos, su preparación y su aplicación terapéutica | |
| CY1116901T1 (el) | Εμβολιο που περιλαμβανει προϊοντα συζευξης καψικου πολυσακχαριδιου streptococcus pneumoniae | |
| MX347240B (es) | Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos. | |
| BR112022007719A2 (pt) | Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado | |
| BRPI1008855B8 (pt) | derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende | |
| CY1115529T1 (el) | Συνθεση συζυγων πολυμερων των ενωσεων ινδολοκαρβαζολιου | |
| AR092951A1 (es) | Procesos basados en acetales de aldehidos para la fabricacion de depsipeptidos macrociclicos e intermedios | |
| CO2025015728A2 (es) | Conjugados que comprenden enlazadores escindibles | |
| MX2023006799A (es) | Inmunoconjugados anti-cea y usos de estos. | |
| BR112022014391A2 (pt) | Compostos e conjugados dos mesmos | |
| BR112021021728A2 (pt) | Conjugado de anticorpo anti-bcma, composições que compreendem os mesmos e métodos para fazer e usar os mesmos | |
| MX2026001790A (es) | Conjugados que comprenden enlazadores escindibles |